Taking a look at the recent company presentation, this first half looks loaded with very important announcements.
Starting with Orphan Drug and Fast Track designation for Azer-Cell as early as this month. That will be 2 of those designations that IMU holds. Very significant tick for IMU.
Followed by a data update for Vaxinia about the end of March. The first update since November 23. When we got the great news about Cholangio CR and SD . There should be substantially more data at higher doses than the last update.
At the same time we expect our first data from ONCARLYTICS. That will be a big event for long term holders who are invested in the science. It’s been over 5 years since we first met Yuman Fong. This will answer the big question? Have we backed a winner or wasted our time.,
I would suspect the data cuts will happen any day , to send the data off the be analysed ready for publication. Looking at last weeks video, both LC and BG looked very confident!
Then late May or Early June we get ph1B update on Azer-Cel. This will have updated Cohort 2 IL2 data. This could be massive.
At the same time IMU will release details of an expansion trial of Azer-cel for another blood cancer. That’ll be 2 different blood cancers that are proving up Azer-Cel as a ground breaking therapy. And I’d bet they will target a cancer that will lead us to out 3rd ODD and Fast Track. Quite impressive.
Much better progress than other Aussie cancer companies that can’t seem to get an NDA file for a ph1 trial !
So we’ve got a big 4 months of news coming our way. Remember not to get misinformation from the trolls. Plenty of great facts to be found on the IMU website.
View attachment 6792186View attachment 6792186
(20min delay)